Tokyo, May 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061349) titled 'Analysis of Campylobacter glycan-recognizing antibodies related to Guillain-Barre syndrome in human serum' on May 1.
Study Type:
Observational
Primary Sponsor:
Institute - Chiba University
Condition:
Condition - Guillain-Barre syndrome
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To characterize antibodies against Campylobacter lipooligosaccharide(LOS) and gangliosides in human serum, and to determine the types and titers of antibodies associated with the development of Guillain-Barre syndrome.
Basic objectives2 - Bio-equivalence
Eligibility:
Age-lower limit - 15
years-old
=
Gender - Male and Female
Key inclusion criteria - Patients with a confirmed diagnosis of Guillain-Barre syndrome (GBS)
Patients suspected of Guillain-Barre syndrome
Neurology outpatients without GBS
Key exclusion criteria - Individuals who do not provide informed consent to participate in the study
Individuals from whom adequate serum samples cannot be obtained or whose samples are of insufficient quality
Individuals who are receiving immunosuppressive therapy (e.g., high-dose corticosteroids or immunosuppressive agents) that may affect antibody measurements, as judged by the principal investigator
Individuals deemed inappropriate for inclusion in the study by the principal investigator for any other reason
Target Size - 150
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2026 Year 05 Month 01 Day
Date of IRB - 2026 Year 04 Month 06 Day
Anticipated trial start date - 2026 Year 05 Month 01 Day
Last follow-up date - 2028 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000070188
Disclaimer: Curated by HT Syndication.
